Amplia Therapeutics Ltd (ATX) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.028x

Based on the latest financial reports, Amplia Therapeutics Ltd (ATX) has a cash flow conversion efficiency ratio of -0.028x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.09 Million ≈ $-768.53K USD) by net assets (AU$39.47 Million ≈ $27.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ATX market cap overview for the company's overall valuation and market capitalisation.

Amplia Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2010–2026)

This chart illustrates how Amplia Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Amplia Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Amplia Therapeutics Ltd ranked by their cash flow conversion efficiency. See ATX debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Grazziotin S.A SA:CGRA3	0.028x
Bougainville Copper Ltd AU:BOC	-0.143x
Tune Protect Group Bhd KLSE:5230	0.004x
Rothwell International Co. Limited KQ:900260	0.415x
NDL Ventures Limited NSE:NDLVENTURE	0.000x
YOUNGHWA TECH Co. Ltd KQ:265560	0.063x
BII Railway Transportation Technology Holdings Company Limited F:CN6	-0.008x
SelfWealth Limited AU:SWF	0.093x

Annual Cash Flow Conversion Efficiency for Amplia Therapeutics Ltd (2010–2026)

The table below shows the annual cash flow conversion efficiency of Amplia Therapeutics Ltd from 2010 to 2026. View today's stock price for Amplia Therapeutics Ltd for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2026-03-31	AU$39.47 Million ≈ $27.93 Million	AU$-8.73 Million ≈ $-6.18 Million	-0.221x	+32.44%
2025-03-31	AU$21.02 Million ≈ $14.88 Million	AU$-6.89 Million ≈ $-4.87 Million	-0.328x	+27.06%
2024-03-31	AU$11.42 Million ≈ $8.08 Million	AU$-5.13 Million ≈ $-3.63 Million	-0.449x	-34.42%
2023-03-31	AU$15.84 Million ≈ $11.20 Million	AU$-5.29 Million ≈ $-3.74 Million	-0.334x	-65.79%
2022-03-31	AU$21.85 Million ≈ $15.46 Million	AU$-4.40 Million ≈ $-3.11 Million	-0.201x	+28.56%
2021-03-31	AU$10.34 Million ≈ $7.32 Million	AU$-2.92 Million ≈ $-2.06 Million	-0.282x	-16.24%
2020-03-31	AU$8.61 Million ≈ $6.09 Million	AU$-2.09 Million ≈ $-1.48 Million	-0.243x	-112.92%
2019-03-31	AU$8.66 Million ≈ $6.13 Million	AU$-987.35K ≈ $-698.61K	-0.114x	+92.41%
2018-03-31	AU$2.36 Million ≈ $1.67 Million	AU$-3.55 Million ≈ $-2.51 Million	-1.501x	-61.48%
2017-03-31	AU$6.63 Million ≈ $4.69 Million	AU$-6.16 Million ≈ $-4.36 Million	-0.930x	+21.06%
2016-03-31	AU$4.00 Million ≈ $2.83 Million	AU$-4.71 Million ≈ $-3.34 Million	-1.178x	-44.06%
2015-03-31	AU$4.87 Million ≈ $3.44 Million	AU$-3.98 Million ≈ $-2.81 Million	-0.817x	-397.85%
2014-03-31	AU$9.77 Million ≈ $6.91 Million	AU$-1.60 Million ≈ $-1.14 Million	-0.164x	-5.13%
2013-03-31	AU$11.23 Million ≈ $7.95 Million	AU$-1.75 Million ≈ $-1.24 Million	-0.156x	+60.77%
2012-03-31	AU$3.19 Million ≈ $2.26 Million	AU$-1.27 Million ≈ $-899.95K	-0.398x	-50.85%
2011-03-31	AU$6.07 Million ≈ $4.30 Million	AU$-1.60 Million ≈ $-1.13 Million	-0.264x	+22.54%
2010-03-31	AU$5.98 Million ≈ $4.23 Million	AU$-2.04 Million ≈ $-1.44 Million	-0.341x	--

About Amplia Therapeutics Ltd

AU:ATX Australia Biotechnology

Market Cap

$45.40 Million

AU$64.16 Million AUD

Market Cap Rank

#22352 Global

#794 in Australia

Share Price

AU$0.13

Change (1 day)

+0.00%

52-Week Range

AU$0.11 - AU$0.27

All Time High

AU$16.20